OPCI Journal Club: A Conversation with Dr. Patel - DEFINE PCI

Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.

David J. Cohen, MD, MSc is currently Director of Clinical and Outcomes Research at the Cardiovascular Research Foundation (New York, NY) and Director of Academic Affairs at St. Francis Hospital (Roslyn, NY). Previously, he was Professor of Medicine at the University of Missouri–Kansas City and Director of Cardiovascular Research and Medical Director of Health Economics and Technology Assessment at Saint Luke’s Mid America Heart Institute. Heart Institute where he continues to direct the Health Economics and Technology Assessment Group. Dr. Cohen earned his M.D. at Harvard Medical School and his Master's degree in Health Policy at the Harvard School of Public Health. He did his clinical training at Brigham and Women's Hospital and was a clinical and research fellow in cardiology at Beth Israel Hospital for five years. Dr. Cohen is a practicing interventional cardiologist with a focus on structural and valvular heart disease. His research focuses on the application of formal cost-effectiveness methodology to novel interventions for cardiovascular disease (CVD), the extension of traditional cardiovascular outcomes research to include patient-centered outcomes, and the development and evaluation of instruments for assessing CVD patients’ health status and preferences. He is also active in research to determine the short- and long-term outcomes of new devices for percutaneous coronary revascularization and identifying the optimal target populations and techniques for these devices. Dr. Cohen has published more than 500 original articles in leading journals, including the New England Journal of Medicine, Lancet, JAMA, Circulation, and the Journal of the American College. Dr. Cohen serves on the editorial board for the American Heart Journal, JACC Interventions, and Circulation and reviews for the American Journal of Cardiology, Journal of the American College of Cardiology, New England Journal of Medicine, JAMA, and Medical Decision Making.

Dr. Evan Shlofmitz is an Interventional Cardiologist and the Director of Intravascular Imaging at St. Francis Hospital - The Heart Center in Roslyn, NY. He completed a fellowship in Interventional Cardiology at Georgetown University/MedStar Washington Hospital Center. He previously completed an Intravascular Imaging and Physiology fellowship at the Cardiovascular Research Foundation (CRF) and Columbia University Medical Center (CUMC), a Cardiovascular Disease fellowship at Northwell Health and served as Chief Resident for Internal Medicine at New York Presbyterian Queens. He serves on SCAI's IHD Council and is a co-director of Optimizing PCI (OPCI). His research interests have centered on intravascular imaging, the treatment of calcified coronary artery disease, in-stent restenosis and the optimization of stent implantation, with more than 100 publications in peer-reviewed journals.

James Spratt Professor of Interventional cardiology with a sub-speciality interest in complex PCI, intravascular imaging and CTO. He is widely published within this area and has performed live case demonstrations globally. He has an interest in medical education and is the Founder of Optima Education.

An internationally recognized interventional cardiologist, Dr. Moses has performed more than 15,000 interventional procedures, authored over 600 publications, and served as lead investigator for numerous national and international clinical studies that have demonstrated the effectiveness and safety of coronary stent placement. In 2002, Dr. Moses was the lead investigator on a large clinical trial, the first in the U.S. that demonstrated the enormous benefit that led to FDA approval of the first drug-coated stent now used in the majority of interventional procedures in the U.S. Most recently in on the Executive Committee of PARTNER trial; they brought the first transcatheter aortic valve to clinical use in the U.S. He currently serves as Director of Interventional Cardiovascular Therapeutics at Columbia University Medical Center and as Director of Advanced Cardiac Interventions at St Francis Hospital and Heart Center in Roslyn, NY. He is also a pioneer in developing approaches involving minimally invasive surgery, angioplasty, gene therapy, novel imaging technologies and various support devices that allow for wider application of interventional cardiovascular procedures.

Consultant Interventional Cardiologist and Revascularisation Group Chair at Royal Brompton Hospital, London. His clinical focus is on use of intravascular imaging in complex PCI , CTO and cardiogenic shock. His clinical research interests focus on optical coherence tomography, calcific coronary disease and percutaneous ventricular support. Dr Hill was global co-chief investigator for the DISRUPT CAD III study and has served as UK principal investigator for multiple interventional trials. He has served as a CTO and complex PCI proctor on a global basis and works closely with OPTIMA to focus on the development of OPTIMAL PCI. He is the founding co-director of the Complete Revascularisation (CoRe) meetings held every year in London.